This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|July 11, 2017
ABEC Releases 4000-L Single-Use Bioreactor
Author(s)BioPharm International Editors
ABEC increases the maximum capacity of its Custom Single Run Bioreactors to 4000 L, doubling the industry standard.
Advertisement
ABEC, a provider of integrated solutions and services for biopharmaceutical manufacturing, announced on July 10, 2017 the release of single-use bioreactors with production volumes of 4000 L. The company reports that it is the only supplier able to provide single-use bioreactors with capacities greater than 2000 L.
The 4000-L capability enables a reduction in capital, facility, and disposables cost by doubling cell culture capacity in approximately the same floor space. The number of systems and disposable containers needed is cut in half, and facility size is reduced.
The 4000-L CSR Bioreactor has demonstrated performance comparable to stainless steel systems, a key feature of the company’s Custom Single Run (CSR) product line. Features of the line include large production volumes, performance comparable to stainless steel systems, seamless process transfer and scale-up, rapid container loading, and a non-proprietary supply chain, the company reports.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5